Home Neurological Disorders Alzheimers Jabbing at Alzheimer’s: AC Immune Takes Precision Approach to Vaccines

Conceptual illustration of neuron cells with glowing link knots. Synapse and neuron cells sending electrical chemical signals. Neuron of Interconnected neurons with electrical pulses, 3D illustration — Conceptual illustration of neuron cells with glowing link knots. Synapse and Neuron cells sending electrical chemical signals. Neuron of Interconnected neurons with electrical pulses. 3D illustration

Jabbing at Alzheimer’s: AC Immune Takes Precision Approach to Vaccines

The Swiss biopharma shows early clinical data for Janssen-partnered pTau shot and preclinical success for the wholly-owned prospect targeting Aβ amyloid.

By Alex Philippidis

-

March 2, 2022

[Source: AC Immune]

Based on the high-dose data, AC Immune intends to advance to later-stage development of ACI-35.030, which according to the company is the first AD vaccine candidate designed to generate antibodies targeting pathological pTau in the brain. The company also plans to launch clinical studies of the optimized ACI-24 during the first half of this year . . .

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

MORE STORIES